<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336195">
  <stage>Registered</stage>
  <submitdate>4/11/2010</submitdate>
  <approvaldate>5/11/2010</approvaldate>
  <actrnumber>ACTRN12610000950066</actrnumber>
  <trial_identification>
    <studytitle>Fibrinolytic treatment of acute respiratory failure due to inflammatory lung injury</studytitle>
    <scientifictitle>Fibrinolytic treatment of acute respiratory failure due to inflammatory lung injury to assess improvement in alveolar dead space and right ventricular function</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Not applicable</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>acute respiratory failure due to inflammatory lung injury</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Administration of tissue plasminogen activator (t-PA) on one occasion.

Dose escalation study 

The first 4 patients will receive 

1.	10 mg bolus and 10 mg over 30 min.

The second 4 patients will receive

2.	10 mg bolus and 20 mg over 30 min.

The final 4 patients will receive

3.	10 mg bolus and 40 mg over 30 min.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Phase 1 study

Alveolar dead space will be assessed using an expired breath carbon dioxide analyser</outcome>
      <timepoint>baseline and at 1 and 4 hours post t-pa</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>pulmonary artery pressure and cardiac function will be assessed using echocardiology</outcome>
      <timepoint>baseline and at 1 and 4 hours post t-pa</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>safety (bleeding) will be assessed by monitoring of the patient in the Intensive Care Unit for fall in Haemoglobin levels or clinical evidence of bleeding</outcome>
      <timepoint>in 24 hours following the t-pa</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>urinary albumin creatinine ratio will be assessed by analysing albumin and creatinine levels in the urine</outcome>
      <timepoint>baseline and at 1 and 4 hours post t-pa</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with acute respiratory failure due to an acute inflammatory insult. 
Requiring positive pressure ventilation via an endo-tracheal tube. 
Impaired oxygenation - arterial partial pressure of oxygen to inspire fraction of oxygen ratio (P/F) &lt;300 mmHg. 
At least one quadrant of pulmonary infiltrate present on CXR.
Enrolled within 24 hrs of developing all of these criteria.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known hypersensitivity to alteplase (t-PA)
Aspirin in the last week
Any therapeutic anti-coagulant therapy 
Significant bleeding disorder within the past six months
Any history of brain or spinal injury including trauma, stroke, transient ischaemic attack, neoplasm, surgery, infection, aneurysm or intracranial bleed. 
Uncontrolled hypertension, systolic blood pressure (BP) &gt;185 mmHg or diastolic BP &gt;110 mmHg.
Recent (within ten days) prolonged or traumatic cardiopulmonary resuscitation (&gt; 2 minutes), obstetric delivery, organ biopsy, puncture of non-compressible blood vessel (e.g. subclavian vein), major surgery or significant trauma.
Documented ulcerative gastrointestinal disease during the last three months.
Arterial aneurysms, arterial/venous malformations.
Neoplasm with increased bleeding risk.
Bacterial endocarditis, pericarditis.
Acute pancreatitis. 
Severe hepatic disease/ dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) or active hepatitis.
Age &lt;18 or &gt; 75
Pulmonary haemorrhage in previous 12 months
Major surgery planned over the next 2 days
Diabetic haemorrhagic retinopathy or other haemorrhagic ophthalmic conditions.
Unlikely to survive 24 hours
Platelet count below 80,000/mm3</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>not applicable</concealment>
    <sequence>not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>not applicable</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>12/12/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital</primarysponsorname>
    <primarysponsoraddress>Victoria Pde, Fitzroy, Victoria, 3065</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Barry Dixon</fundingname>
      <fundingaddress>St Vincent's Hospital Fitzroy, Victoria, 3065</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Inflammatory insults including pneumonia, sepsis, aspiration, trauma, prolonged hypotension, cardiac surgery and pancreatitis can cause lung damage. One mechanism by which inflammation mediates lung injury is through deposition of fibrin in the pulmonary microcirculation. This study will investigate if limiting fibrin deposition through administration of tissue plasminogen activator reduces lung damage.</summary>
    <trialwebsite>none</trialwebsite>
    <publication>none</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Fitzroy, Victoria, 3065</ethicname>
      <ethicaddress>41 Victoria Pde, Fitzroy, Victoria, 3065</ethicaddress>
      <ethicapprovaldate>29/10/2010</ethicapprovaldate>
      <hrec>1/10/0129</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>ICU St.Vincent's Hospital 41 Victoria Pde, Fitzroy, Melbourne, Victoria, 3065</address>
      <phone>61 0439618815</phone>
      <fax />
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>ICU St.Vincent's Hospital 41 Victoria Pde, Melbourne, Victoria, 3065</address>
      <phone>61 0439618815</phone>
      <fax />
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>ICU St.Vincent's Hospital 41 Victoria Pde, Melbourne, Victoria, 3065</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>